Literature DB >> 17631213

The Framingham predictive instrument in chronic kidney disease.

Daniel E Weiner1, Hocine Tighiouart, Essam F Elsayed, John L Griffith, Deeb N Salem, Andrew S Levey, Mark J Sarnak.   

Abstract

OBJECTIVES: We sought to determine the utility of the Framingham equations in individuals with chronic kidney disease (CKD).
BACKGROUND: The Framingham equations predict incident coronary disease. The utility of these equations is unknown in CKD.
METHODS: We pooled individuals without pre-existing coronary disease age 45 to 74 years from the ARIC (Atherosclerosis Risk In Communities) and CHS (Cardiovascular Health Study) trials with CKD, defined by an estimated glomerular filtration rate of 15 to 60 ml/min/1.73 m(2). Using gender-specific models, we determined 5- and 10-year risk of incident myocardial infarction and fatal coronary disease, and evaluated discriminative and calibration ability of the Framingham equations for predicting coronary events.
RESULTS: There were 577 women and 357 men with CKD. Thirty-five men (9.8%) and 30 women (5.2%) and 74 men (20.7%) and 56 women (9.7%) had cardiac events within 5 and 10 years, respectively; 5-year events were predicted in 6.0% and 1.9% and 10-year events in 13.9% and 4.8% of men and women, respectively. For 5-year events, C-statistics assessing discrimination were 0.62 and 0.77, while 10-year C-statistics were 0.60 and 0.73 for men and women, respectively. Calibration was also poor, with Framingham scores generally underpredicting events in individuals with CKD at 5 and 10 years. Discrimination was significantly improved by refitting models with population-specific coefficients, while recalibration improved prediction in women.
CONCLUSIONS: The Framingham instrument demonstrates poor overall accuracy in predicting cardiac events in individuals with CKD, although refit models can substantially improve discrimination. Calibration in women can be moderately improved with adjustment for higher event rates. Development of CKD-specific equations is needed.

Entities:  

Mesh:

Year:  2007        PMID: 17631213     DOI: 10.1016/j.jacc.2007.03.037

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  101 in total

1.  Contrasting Cholesterol Management Guidelines for Adults with CKD.

Authors:  Lisandro D Colantonio; Usman Baber; Maciej Banach; Rikki M Tanner; David G Warnock; Orlando M Gutiérrez; Monika M Safford; Christoph Wanner; George Howard; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2014-11-13       Impact factor: 10.121

Review 2.  PCSK9 in chronic kidney disease.

Authors:  P Pavlakou; E Liberopoulos; E Dounousi; M Elisaf
Journal:  Int Urol Nephrol       Date:  2017-01-13       Impact factor: 2.370

Review 3.  Clinical imaging for prevention: directed strategies for improved detection of presymptomatic patients with undetected atherosclerosis--Part I: Clinical imaging for prevention.

Authors:  Leslee J Shaw; Daniel S Berman; Roger S Blumenthal; Matthew J Budoff; Tracy L Faber; Tauqir Goraya; Sandra S Halliburton; Harvey Hecht; Hosen Kiat; Wolfgang Koenig; Shaista Malik; Michael Merhige; Khurram Nasir; James K Min; James O'Keefe; Donna M Polk; Paolo Raggi; Jeffrey A Rosenblatt; Ronald G Schwartz; Allen J Taylor; Gregory S Thomas; William Wijns
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

Review 4.  Endothelial progenitor cells and endothelial vesicles - what is the significance for patients with chronic kidney disease?

Authors:  Rajesh Mohandas; Mark S Segal
Journal:  Blood Purif       Date:  2010-01-08       Impact factor: 2.614

5.  Defining incident chronic kidney disease in the research setting: The ARIC Study.

Authors:  Lori D Bash; Josef Coresh; Anna Köttgen; Rulan S Parekh; Tibor Fulop; Yaping Wang; Brad C Astor
Journal:  Am J Epidemiol       Date:  2009-06-17       Impact factor: 4.897

6.  The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD.

Authors:  Giovana S Di Marco; Stefan Reuter; Uta Hillebrand; Susanne Amler; Maximilian König; Etienne Larger; Hans Oberleithner; Eva Brand; Hermann Pavenstädt; Marcus Brand
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

Review 7.  Epidemiology of dyslipidemia in chronic kidney disease.

Authors:  Kunitoshi Iseki
Journal:  Clin Exp Nephrol       Date:  2014-01-11       Impact factor: 2.801

Review 8.  Non-invasive risk assessment in patients with chronic kidney disease.

Authors:  Abdul Hakeem; Sabha Bhatti; Alejandro R Trevino; Zainab Samad; Su Min Chang
Journal:  J Nucl Cardiol       Date:  2011-05       Impact factor: 5.952

9.  Screening for CKD with eGFR: doubts and dangers.

Authors:  Richard J Glassock; Christopher Winearls
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

10.  Kidney function and estimated vascular risk in patients with primary dyslipidemia.

Authors:  Konstantinos Tziomalos; Emmanuel S Ganotakis; Irene F Gazi; Devaki R Nair; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.